METAFORA develops a disruptive blood-based In Vitro Diagnostic platform called METAdiag. METAdiag monitors cells’ energetic needs thanks to unique, proprietary biomarkers (Receptor Binding Domains or RBDs), able to quantify nutrient transporters used by cells to feed on glucose, amino acids, vitamins and other essential nutrients at the cell’s surface.
Cutting edge algorithms using Artificial Intelligence to handle big data participate in generating actionable results for physicians’ routine clinical practice. METAglut1TM is a first test developed to fill a medical unmet need, i.e. the easy and early diagnosis of a debilitating but curable neuro-metabolic disease in children, the Glut1 Deficiency Syndrome. Following encouraging results of a pilot study published in a leading scientific journal, the CE-mark of the test and a first commercial agreement with CERBA Healthcare, a leading medical testing laboratory, METAFORA successfully concluded a prospective validation study of METAglut1TM in 33 hospitals in France (one of the main objectives of our project). In addition to this validation study, we also obtained consistent positive results from smaller clinical studies in Germany and Italy, paving the way to the international deployment of the test. At the end of phase 2 of the project, we are thus in prime position to a go-to-market status by the end of 2021 (TRL 9 for METAglut1TM).
After 7 years of commercialization, we expect sales of close to 317 000 tests, at an end-user price of 300 € per test, including analysis and report. By 2025, we expect to exceed breakeven with an EBITDA of over € 1m. After a 7-year commercialization phase, we will have generated close to € 50m in cumulated revenues.
